Rapid and Reliable HLA-B59:01* Genotyping to Prevent Carbonic Anhydrase Inhibitor-Induced Severe Cutaneous Adverse Reactions.

IF 1.1 4区医学 Q4 MEDICAL LABORATORY TECHNOLOGY Annals of clinical and laboratory science Pub Date : 2024-01-01

Ji Young Huh, Yong Ju Song, Geon Park

{"title":"Rapid and Reliable HLA-B*59:01 Genotyping to Prevent Carbonic Anhydrase Inhibitor-Induced Severe Cutaneous Adverse Reactions.","authors":"Ji Young Huh, Yong Ju Song, Geon Park","doi":"","DOIUrl":null,"url":null,"abstract":"Objective: Carbonic anhydrase inhibitors (CAIs) are intraocular pressure-reducing medications used in ophthalmology. Human leukocyte antigen-B*59:01 (HLA-B*59:01) is strongly associated with CAI-induced severe cutaneous adverse reactions (SCARs). This study aimed to develop and validate a rapid and economical screening method for HLA-B*59:01 to prevent carbonic anhydrase inhibitor-induced SCARs.Methods: Duplex allele-specific polymerase chain reaction (PCR) with an internal control was performed for HLA-B*59:01 genotyping. The accuracy of duplex allele-specific PCR for HLA-B*59:01 genotyping was evaluated in 200 blood samples, using sequence-based typing (SBT) as the reference method.Results: In total, 50 HLA-B*59:01-positive and 150 HLA-B*59:01-negative results obtained using duplex allele-specific PCR were in complete agreement with the SBT results.Conclusion: Duplex allele-specific PCR is a rapid, reliable, and economical assay for screening the HLA-B*59:01 allele.","PeriodicalId":8228,"journal":{"name":"Annals of clinical and laboratory science","volume":"54 1","pages":"101-105"},"PeriodicalIF":1.1000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of clinical and laboratory science","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Carbonic anhydrase inhibitors (CAIs) are intraocular pressure-reducing medications used in ophthalmology. Human leukocyte antigen-B*59:01 (HLA-B*59:01) is strongly associated with CAI-induced severe cutaneous adverse reactions (SCARs). This study aimed to develop and validate a rapid and economical screening method for HLA-B*59:01 to prevent carbonic anhydrase inhibitor-induced SCARs.

Methods: Duplex allele-specific polymerase chain reaction (PCR) with an internal control was performed for HLA-B*59:01 genotyping. The accuracy of duplex allele-specific PCR for HLA-B*59:01 genotyping was evaluated in 200 blood samples, using sequence-based typing (SBT) as the reference method.

Results: In total, 50 HLA-B*59:01-positive and 150 HLA-B*59:01-negative results obtained using duplex allele-specific PCR were in complete agreement with the SBT results.

Conclusion: Duplex allele-specific PCR is a rapid, reliable, and economical assay for screening the HLA-B*59:01 allele.

微信好友朋友圈 QQ好友复制链接

本刊更多论文

快速可靠的 HLA-B*59:01 基因分型可预防碳酸酐酶抑制剂引起的严重皮肤不良反应。

目的：碳酸酐酶抑制剂（CAI）是用于眼科的眼压降低药物。人类白细胞抗原-B*59:01（HLA-B*59:01）与 CAI 引起的严重皮肤不良反应（SCARs）密切相关。本研究旨在开发并验证一种快速、经济的 HLA-B*59:01 筛查方法，以预防碳酸酐酶抑制剂诱发的 SCARs：方法：采用带有内对照的双等位基因特异性聚合酶链反应（PCR）进行HLA-B*59:01基因分型。以基于序列的分型（SBT）为参照方法，在 200 份血液样本中评估了双等位基因特异性 PCR 用于 HLA-B*59:01 基因分型的准确性：结果：使用双工等位基因特异性 PCR 获得的 50 个 HLA-B*59:01 阳性结果和 150 个 HLA-B*59:01 阴性结果与 SBT 结果完全一致：双重等位基因特异性 PCR 是一种快速、可靠、经济的 HLA-B*59:01 等位基因筛查方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Annals of clinical and laboratory science 医学-医学实验技术

CiteScore

1.60

自引率

0.00%

发文量

112

审稿时长

6-12 weeks

期刊介绍： The Annals of Clinical & Laboratory Science welcomes manuscripts that report research in clinical science, including pathology, clinical chemistry, biotechnology, molecular biology, cytogenetics, microbiology, immunology, hematology, transfusion medicine, organ and tissue transplantation, therapeutics, toxicology, and clinical informatics.